id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-300950-ag0sql4i	Lin, John	Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment	2020-06-05		.txt	text/plain	1899	104	50	Several case reports including the first report of SARS outbreak described the use of the anti-viral drug ribavirin and a corticosteroid in patients with contradictory clinical outcomes. In several studies, lopinavir/ritonavir was shown to have anti-CoV effects in vitro, in MERS-infected primate models, and in SARS-infected humans. Furthermore, in a single MERS patient, a triple-combination therapy of ribavirin, IFN and lopinavir/ ritonavir resolved viremia in 2 days following initiation of treatment. [7] [8] [9] In two reports from China and Korea, the use of lopinavir/ritonavir in patients with COVID-19 improved recovery and reduced viral load. [7, 8] However, Chen et al [9] showed that lopinavir/ ritonavir and the anti-influenza treatment Arbidol had no clinically significant improvement in 134 people with mild COVID-19. [17] In an effort to combat inflammation and improve clinical outcome, corticosteroid use has been described in SARS, MERS, and COVID-19.	./cache/cord-300950-ag0sql4i.txt	./txt/cord-300950-ag0sql4i.txt